Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Variations in Screening Quality in a Federal Colorectal Cancer Screening Program for the Uninsured.

Nadel MR, Royalty J, Joseph D, Rockwell T, Helsel W, Kammerer W, Gray SC, Shapiro JA.

Prev Chronic Dis. 2019 May 30;16:E67. doi: 10.5888/pcd16.180452.

2.

Increasing Colorectal Cancer Screening in Health Care Systems Using Evidence-Based Interventions.

DeGroff A, Sharma K, Satsangi A, Kenney K, Joseph D, Ross K, Leadbetter S, Helsel W, Kammerer W, Firth R, Rockwell T, Short W, Tangka F, Wong F, Richardson L.

Prev Chronic Dis. 2018 Aug 9;15:E100. doi: 10.5888/pcd15.180029. No abstract available.

3.

Erratum to: The effectiveness of targeting never or rarely screened women in a national cervical cancer screening program for underserved women.

Benard VB, Royalty J, Saraiya M, Rockwell T, Helsel W.

Cancer Causes Control. 2015 May;26(5):721. doi: 10.1007/s10552-015-0586-4. No abstract available.

PMID:
25948086
4.

Clinical outcomes of mammography in the National Breast and Cervical Cancer Early Detection Program, 2009-2012.

White A, Miller J, Royalty J, Ryerson AB, Benard V, Helsel W, Kammerer W.

Cancer Causes Control. 2015 May;26(5):723-32. doi: 10.1007/s10552-015-0567-7. Epub 2015 Mar 26.

5.

The effectiveness of targeting never or rarely screened women in a national cervical cancer screening program for underserved women.

Benard VB, Royalty J, Saraiya M, Rockwell T, Helsel W.

Cancer Causes Control. 2015 May;26(5):713-9. doi: 10.1007/s10552-015-0542-3. Epub 2015 Mar 10. Erratum in: Cancer Causes Control. 2015 May;26(5):721.

6.

Clinical outcomes from the CDC's Colorectal Cancer Screening Demonstration Program.

Seeff LC, Royalty J, Helsel WE, Kammerer WG, Boehm JE, Dwyer DM, Howe WR Jr, Joseph D, Lane DS, Laughlin M, Leypoldt M, Marroulis SC, Mattingly CA, Nadel MR, Phillips-Angeles E, Rockwell TJ, Ryerson AB, Tangka FK.

Cancer. 2013 Aug 1;119 Suppl 15:2820-33. doi: 10.1002/cncr.28163.

7.

Timeliness of cervical cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program.

Benard VB, Howe W, Royalty J, Helsel W, Kammerer W, Richardson LC.

J Womens Health (Larchmt). 2012 Jul;21(7):776-82. doi: 10.1089/jwh.2011.3224. Epub 2012 Apr 16.

8.

Timeliness of breast cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program, 1996-2005.

Richardson LC, Royalty J, Howe W, Helsel W, Kammerer W, Benard VB.

Am J Public Health. 2010 Sep;100(9):1769-76. doi: 10.2105/AJPH.2009.160184. Epub 2009 Dec 17.

9.

Assessment of follow-up for low-grade cytological abnormalities in the National Breast and Cervical Cancer Early Detection Program, 2000-2005.

Benard VB, Howe W, Saraiya M, Helsel W, Lawson HW.

J Low Genit Tract Dis. 2008 Oct;12(4):300-6. doi: 10.1097/LGT.0b013e31817e308e.

PMID:
18820545
10.

A combined approach to women's health is associated with a greater likelihood of repeat mammography in a population of financially disadvantaged women.

Gregory-Mercado KY, Will J, True S, Royalty J, Starcher ET 2nd, Khavjou O, Helsel W, Kammerer W, Howe W.

Prev Chronic Dis. 2007 Oct;4(4):A89. Epub 2007 Sep 15.

11.

Breast cancer screening among low-income or uninsured women: results from the National Breast and Cervical Cancer Early Detection Program, July 1995 to March 2002 (United States).

Eheman CR, Benard VB, Blackman D, Lawson HW, Anderson C, Helsel W, Lee NC.

Cancer Causes Control. 2006 Feb;17(1):29-38.

PMID:
16411050
12.

Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women.

Benard VB, Lawson HW, Eheman CR, Anderson C, Helsel W.

Obstet Gynecol. 2005 Jun;105(6):1323-8.

PMID:
15932824
13.

Serum carotenoids and alpha-tocopherol and risk of nonmelanoma skin cancer.

Dorgan JF, Boakye NA, Fears TR, Schleicher RL, Helsel W, Anderson C, Robinson J, Guin JD, Lessin S, Ratnasinghe LD, Tangrea JA.

Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1276-82.

14.

Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001.

Benard VB, Eheman CR, Lawson HW, Blackman DK, Anderson C, Helsel W, Thames SF, Lee NC.

Obstet Gynecol. 2004 Mar;103(3):564-71.

PMID:
14990422
15.

Risk factors for the development of placebo adverse reactions in a multicenter clinical trial.

Tangrea JA, Adrianza ME, Helsel WE.

Ann Epidemiol. 1994 Jul;4(4):327-31.

PMID:
7921323
16.

Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. The Isotretinoin-Basal Cell Carcinomas Study Group.

Tangrea JA, Adrianza E, Helsel WE, Taylor PR, Hartman AM, Peck GL, Edwards BK.

Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):375-80.

17.

Isotretinoin and the axial skeleton.

Tangrea JA, Taylor PR, Hartman AM, Edwards BK, Kilcoyne RF, Helsel WE, Adrianza ME, Peck GL.

Lancet. 1992 Aug 22;340(8817):495-6. No abstract available.

PMID:
1354829
18.

Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin.

Tangrea JA, Kilcoyne RF, Taylor PR, Helsel WE, Adrianza ME, Hartman AM, Edwards BK, Peck GL.

Arch Dermatol. 1992 Jul;128(7):921-5.

PMID:
1626958
19.

Patients' perceptions on participation in a cancer chemoprevention trial.

Tangrea JA, Adrianza ME, Helsel WE.

Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(3):325-30. No abstract available.

PMID:
11656233
20.

Patients' perceptions on participation in a cancer chemoprevention trial.

Tangrea JA, Adrianza ME, Helsel WE.

Cancer Epidemiol Biomarkers Prev. 1992 May-Jun;1(4):325-30.

21.

The Aberrant Behavior Checklist with children and adolescents with dual diagnosis.

Rojahn J, Helsel WJ.

J Autism Dev Disord. 1991 Mar;21(1):17-28.

PMID:
2037547
22.

Physical activity and risk of large bowel cancer in the Framingham Study.

Ballard-Barbash R, Schatzkin A, Albanes D, Schiffman MH, Kreger BE, Kannel WB, Anderson KM, Helsel WE.

Cancer Res. 1990 Jun 15;50(12):3610-3.

23.

Body fat distribution and breast cancer in the Framingham Study.

Ballard-Barbash R, Schatzkin A, Carter CL, Kannel WB, Kreger BE, D'Agostino RB, Splansky GL, Anderson KM, Helsel WE.

J Natl Cancer Inst. 1990 Feb 21;82(4):286-90.

PMID:
2299677
24.

Treatment of ADDH in mentally retarded children: a preliminary study.

Payton JB, Burkhart JE, Hersen M, Helsel WJ.

J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):761-7.

PMID:
2676965
25.

Is alcohol consumption related to breast cancer? Results from the Framingham Heart Study.

Schatzkin A, Carter CL, Green SB, Kreger BE, Splansky GL, Anderson KM, Helsel WE, Kannel WB.

J Natl Cancer Inst. 1989 Jan 4;81(1):31-5.

PMID:
2908919
26.
27.

Stimulant medication and the retarded.

Helsel WJ, Hersen M, Lubetsky MJ.

J Am Acad Child Adolesc Psychiatry. 1989 Jan;28(1):138-9. No abstract available.

PMID:
2563361
28.
29.

Depression in mentally retarded children.

Matson JL, Barrett RP, Helsel WJ.

Res Dev Disabil. 1988;9(1):39-46.

PMID:
3353541
30.
31.

Fears in children and adolescents: normative data.

Ollendick TH, Matson JL, Helsel WJ.

Behav Res Ther. 1985;23(4):465-7. No abstract available.

PMID:
4026774
32.

Fears in visually-impaired and normally-sighted youths.

Ollendick TH, Matson JL, Helsel WJ.

Behav Res Ther. 1985;23(3):375-8. No abstract available.

PMID:
4004716
33.
34.

The assessment of depression in children: the internal structure of the Child Depression Inventory (CDI).

Helsel WJ, Matson JL.

Behav Res Ther. 1984;22(3):289-98. No abstract available.

PMID:
6466279
35.

Verbal behaviors in depressed and nondepressed mentally retarded persons.

Matson JL, Senatore V, Kazdin AE, Helsel WT.

Appl Res Ment Retard. 1983;4(1):79-83.

PMID:
6870237
36.

Training visual efficiency in myopic persons.

Matson JL, Helsel WJ, LaGrow SJ.

Behav Res Ther. 1983;21(2):115-8. No abstract available.

PMID:
6838468
37.

Development of a rating scale to assess social skill deficits in mentally retarded adults.

Matson JL, Helsel WJ, Bellack AS, Senatore V.

Appl Res Ment Retard. 1983;4(4):399-407.

PMID:
6670875
38.

Development of a rating scale to measure social skills in children: the Matson Evaluation of Social Skills with Youngsters (MESSY).

Matson JL, Rotatori AF, Helsel WJ.

Behav Res Ther. 1983;21(4):335-40. No abstract available.

PMID:
6626104
39.

Macrophage production of fibronectin, a chemoattractant for fibroblasts.

Tsukamoto Y, Helsel WE, Wahl SM.

J Immunol. 1981 Aug;127(2):673-8.

PMID:
6166682
40.

Report on extraneous materials in foods and drugs.

Helsel WG.

J Assoc Off Anal Chem. 1973 Mar;56(2):310-1. No abstract available.

PMID:
4775497

Supplemental Content

Loading ...
Support Center